Company profile: Accession Therapeutics
1.1 - Company Overview
Company description
- Provider of immuno-oncology therapeutics based on Trocept, a stealth virus platform engineered to selectively enter cancer cells while bypassing healthy cells to deliver broad, potent payloads and minimize systemic toxicity, targeting hard-to-treat cancers. Pipeline includes TROCEPT-01 (immune checkpoint inhibitor), TROCEPT-02 (universal bispecific immune activator), and other targeted programs.
Products and services
- TROCEPT-01: First Trocept-derived drug encoding an immune checkpoint inhibitor, engineered for multiple solid tumor indications and expected to enter clinical trials in 2024, clinical-grade and architected to target cancer cells only
- TROCEPT-02: Second Trocept program encoding a universal bispecific immune activator, slated to begin clinical trials in 2025, modular and precision-targeted to cancer cells while sparing healthy tissues
- Trocept: Stealth viral platform engineered to deliver broad, potent payloads exclusively into cancer cells, bypassing healthy cells to minimize systemic toxicity and address hard-to-treat tumors, custom-engineered
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Accession Therapeutics
Infinity Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug discovery and development focused on medicines for the treatment of cancer and related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinity Pharmaceuticals company profile →
Kymera Therapeutics
HQ: United States
Website
- Description: Provider of targeted protein degradation therapeutics, leveraging TPD to eliminate disease-causing proteins, developing investigational degraders KT-474 (IRAK4) in Phase 2 for hidradenitis suppurativa and atopic dermatitis; KT-333 (STAT3) in Phase 1 for hematological malignancies and solid tumors; and KT-253 (MDM2) in Phase 1 for high-grade myeloid malignancies, lymphomas, and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kymera Therapeutics company profile →
Viventia Bio
HQ: Canada
Website
- Description: Provider of next-generation oncology therapeutics utilizing proprietary Targeted Protein Therapeutic (TPT) technology; a privately held biopharmaceutical company focused on the discovery and development of TPT-based product candidates with potential advantages in treating cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viventia Bio company profile →
ABK Biomedical
HQ: Canada
Website
- Description: Provider of biomaterials solutions for the clinical market, focused on improving treatment options for patients with hypervascular tumors and transforming embolization procedures in interventional radiology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ABK Biomedical company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Accession Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Accession Therapeutics
2.2 - Growth funds investing in similar companies to Accession Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Accession Therapeutics
4.2 - Public trading comparable groups for Accession Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →